Neoplasms Clinical Trial
Contrast-enhanced MRI is the most common way for evaluating neuroepithelial tumor grading and monitoring for tumor recurrence,but the ability to predict tumor behavior remains very limited.In this study, the investigators will use multi-b-value diffusion-weighted imaging(DWI),three-dimensional arterial spin labeling(3D-ASL) and dynamic contrast-enhanced MRI imaging(DCE) to evaluate neuroepithelial tumor grading and monitor for tumor recurrence.
Glioma is classified into 4 grades, with worse prognosis for more advanced grades.Previous
studies have suggested that different therapeutic strategies should be applied for gliomas
at different grades,so glioma grading before the operation is therefore of important
clinical significance for guiding the grade-dependent therapeutic strategy.
Combination temozolomide and radiation significantly prolongs survival compared with
radiation alone and has become standard treatment for Patients with high-grade glioma.
Response assessment in these patients is difficult as a result of the frequent occurrence of
early imaging changes indistinguishable from tumor progression, termed pseudoprogression.
The majority of patients remain clinically stable. It is often unclear whether current
therapy should be maintained or second-line therapy initiated.
The ADC value can potentially reveal the differences in cellularity and nuclear atypia of
gliomas1. Theoretically, high cellularity in advanced gliomas may impede free water
diffusion and thus lead to a decreased ADC value.In several previous studies,recurrent
tumors have shows significantly higher cellularity than those shown by
pseudoprogression.Such high cellularity is associated with relative reductions in
extracellular space when compared with low cellularity, resulting in decreased diffusivity
of water molecules in the former circumstance when compared with the latter. DWI measures
the degree of water diffusion within tissue Apparent diffusion coefficient (ADC) values
quantify the mobility of water molecules at the cellular level, holding the potential to
differentiate between necrosis, edema and recurrent tumor.
A potential mechanism of pseudoprogression is that radiation-induced vascular changes may
lead to focal transient increase in gadolinium enhancement.Three-dimensional arterial spin
labeling(3D-ASL) and dynamic contrast-enhanced (DCE) MRI imaging provides a noninvasive
means for quantifying tumor vascular properties.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Completed |
NCT03190811 -
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
|
Phase 1/Phase 2 |